Managing SGLT2 Inhibitor-Associated Genital Mycotic Infections
Genital mycotic infection is listed as a potential adverse effect of the SGLT2 inhibitor class.
Fungal Infections
Musculoskeletal Malformations Up With Fluconazole in Pregnancy
But no increase seen in conotruncal malformations, oral clefts with use of oral fluconazole in first trimester
Generic Version of Antifungal Drug Mycamine Now Available
Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).
FDA Approves Jublia for Onychomycosis in Pediatric Patients
At week 52, results showed that 65% of patients achieved mycologic cure.
Ibrexafungerp Effective in Second Phase 3 Vulvovaginal Candidiasis Trial
Scynexis announced positive topline results from a second phase 3 study of ibrexafungerp for the treatment of vulvovaginal candidiasis.
App Allows Clinicians to Report on New Uses of FDA-Approved Drugs for Difficult-to-Treat Infectious Diseases
The Food and Drug Administration (FDA) has launched CURE ID, an internet-based repository that allows clinicians to report their experiences using existing FDA-approved drugs for difficult-to-treat infections.
Antibiotic-Resistant Infections: CDC 2019 Threat Report
For the first time, the CDC used electronic health data to calculate the estimates of infection and death associated with healthcare-associated pathogens.
Olorofim Receives Breakthrough Therapy Designation for Invasive Fungal Infections
The Food and Drug Administration has granted Breakthrough Therapy designation to olorofim (formerly F901318; F2G) for the treatment of invasive mold infections in patients with limited or no treatment options, including aspergillosis refractory or intolerant to currently available therapy, and infections due to Lomentospora prolificans, Scedosporium, and Scopulariopsis species. Olorofim is part of a new…
Oral Ibrexafungerp Effective in Vulvovaginal Candidiasis Trial
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes
Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.
